Our study details the molecular mechanism of the Cobll1/PACSIN2/SH3BP1 pathway in regulating drug resistance in CML and presents a potential pharmacological target to overcome TKI resistance and BC progression in CML. This evidence concerns the gene COBLL1 and chronic myelogenous leukemia, BCR-ABL1 positive.